# A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

> **NCT06016842** · PHASE3 · RECRUITING · sponsor: **Ipsen** · enrollment: 276 (estimated)

## Conditions studied

- Primary Biliary Cholangitis (PBC)

## Interventions

- **DRUG:** Elafibranor
- **OTHER:** Matched 80 mg placebo

## Key facts

- **NCT ID:** NCT06016842
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2029-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016842, "A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06016842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*